Shandong Weigao completes share repurchase, boosting treasury holdings

Shandong Weigao Group Medical Polymer Company Limited completed a share repurchase on December 8, 2025, buying back 420,000 ordinary H shares on the Exchange. The repurchased shares represent 0.0093% of the company's issued shares (excluding treasury shares) prior to the event. The transactions were executed at prices ranging from HK$5.4 to HK$5.48 per share, with an aggregate price paid of HK$2,282,000. These shares will be held as treasury shares, increasing the total from 27,709,200 to 28,129,200.

Following the repurchase, the total number of issued shares remains unchanged at 4,522,332,324, with the number of issued shares (excluding treasury shares) slightly decreasing to 4,494,203,124. The repurchase was conducted under a mandate granted on May 27, 2025, which authorized the company to repurchase up to 451,560,392 shares. To date, 21,480,800 shares have been repurchased on the Exchange under this mandate, representing 4.757% of the issued shares (excluding treasury shares) at the resolution date.

A moratorium period is in effect until January 7, 2026, for any new share issues or sales or transfers of treasury shares following this repurchase. This disclosure was submitted by Phillis Wong, the company secretary.